Mp87-05 superior efficacy of degarelix as neoadjuvant hormone therapy in control of acute genitourinary toxicity associated with radiation therapy for prostate cancer compared to lhrh agonist; a propensity-score matching analysis
Degarelix has been reported to offer superior control of lower urinary tract symptoms (LUTS) compared to luteinizing hormone-releasing hormone (LHRH) agonist. However, whether degarelix can reduce acute genitourinary toxicity associated with irradiation when used as neoadjuvant androgen-deprivation therapy (ADT) remains unclear. The aim of this study was to evaluate the efficacy of degarelix as neoadjuvant ADT followed by radiation therapy in the control of acute genitourinary toxicity compared to LHRH agonist.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Junpei Iizuka, Yasunobu Hashimoto, Tsunenori Kondo, Keisuke Hata, Toshio Takagi, Taichi Kanzawa, Kazuhiko Yoshida, Kazunari Tanabe Tags: Prostate Cancer: Advanced (including Drug Therapy) IV Source Type: research
More News: Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Prostate Cancer | Radiation Therapy | Study | Toxicology | Urology & Nephrology